AAM
JAZZ icon

Arabesque Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Arabesque Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,385
Closed -$1.22M – 107
2020
Q4 		$1.22M Sell
7,385
-13,634
-65% -$2.03M 0.36% 47
2020
Q3 		$3M Buy
+21,019
New +$2.61M 2.7% 5

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Arabesque Asset Management's JAZZ Position: Q1 2021 in Review

Arabesque Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2021, closing a stake of 7,385 shares — an estimated $1.22M sold.

Arabesque Asset Management first reported a position in JAZZ in Q3 2020 and held it in 2 quarters. The position peaked at $3M in Q3 2020. 441 funds tracked by Wall St. Rank hold JAZZ as of Q1 2021.

  • Arabesque Asset Management reported no remaining Jazz Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Arabesque Asset Management sold 7,385 Jazz Pharmaceuticals shares in Q1 2021, an estimated $1.22M.
  • Arabesque Asset Management first reported a position in Jazz Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Arabesque Asset Management's Jazz Pharmaceuticals position peaked at $3M in Q3 2020.
  • 441 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2021.

Based on Arabesque Asset Management's 13F filing for Q1 2021, filed 17 May 2021.